BMYMP - Albireo Corporate Updates And Other News: The Good Bad And Ugly Of Biopharma
Albireo looks robust after providing corporate updates
Albireo Pharma Inc. (ALBO) announced its corporate updates while announcing its financial numbers for the second quarter of the year. The company also reported the impact of COVID-19 outbreak on its operations. Albireo also announced the launch of its Expanded Access Program pertaining odevixibat for eligible patients suffering from PFIT in the United States, Canada, Europe, and Australia.
For its second quarter of the year, the company earned $1.9 million, up from $1.3 million it had earned for the corresponding quarter of the previous year. The company stated